Sugi Predict

Sugi Predict / Compounds / SCHEMBL385838

SCHEMBL385838

SCHEMBL385838

CC(N)CNC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.46
▸ CA1 P00915 2/20 0.44
▸ CA2 P00918 2/20 0.44
▸ CA7 P43166 1/20 0.44
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44
▸ CTSS P25774 3/20 0.43
▸ CTSK P43235 3/20 0.43
▸ CTSL P07711 1/20 0.43
▸ CTSB P07858 1/20 0.43
▸ AAK1 Q2M2I8 1/20 0.41
▸ SYK P43405 1/20 0.40
▸ SERPINE1 P05121 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ PCSK9 Q8NBP7 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735620 1.00 MEN1 (0.47) MEN1GAAKMT2ATDP1CA1
SCHEMBL3363685 1.00 MEN1 (0.47) MEN1GAAKMT2ATDP1CA1
Hydrochloric Acid SCHEMBL15136639 0.98 MEN1 (0.46) MEN1GAAKMT2ATDP1CA1
Hydrochloric Acid SCHEMBL17389225 0.98 MEN1 (0.46) MEN1GAAKMT2ATDP1CA1
Hydrochloric Acid SCHEMBL15649122 0.98 MEN1 (0.46) MEN1GAAKMT2ATDP1CA1
SCHEMBL8362351 0.88 MEN1 (0.41) MEN1GAAKMT2ATDP1CA1
Butylamine SCHEMBL28495559 0.86 MEN1 (0.41) MEN1GAAKMT2ATDP1CA1
SCHEMBL2748354 0.86 MEN1 (0.49) MEN1GAAKMT2ATDP1CA1
SCHEMBL703220 0.85 CYP2D6 (0.37) MEN1GAAKMT2ATDP1CA1
SCHEMBL2723370 0.85 CA1 (0.46) MEN1GAAKMT2ATDP1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 400 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118125963-A Perovskite film layer passivating agent, and preparation method and application thereof 福州大学 2024-06-04 — — CN claimed
EP-4729127-A2 BCL6 INHIBITORS Cancer Research Technology Limited (GB) 2026-04-22 — — EP disclosed
US-20260042776-A1 BCL6 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2026-02-12 — — US disclosed
US-12486285-B2 BCL6 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-12-02 — — US disclosed
WO-2025122956-A1 COMBINATION THERAPY VIVACE THERAPEUTICS, INC. (US) 2025-06-12 — — WO disclosed
CN-120035670-A RNAi agents for inhibiting expression of diacylglycerol-O-acyltransferase 2 and uses thereof 云合智药（苏州）生物科技有限公司 2025-05-23 — — CN disclosed
EP-4552695-A2 TYROSINE KINASES INHIBITORS AND USES THEREOF Great Novel Therapeutics Biotech & Medicals Corporation (TW) 2025-05-14 — — EP disclosed
CN-119841776-A Tyrosine kinase inhibitors and uses thereof 华上生技医药股份有限公司 2025-04-18 — — CN disclosed
US-20250120967-A1 TYROSINE KINASES INHIBITORS AND USES THEREOF Great Novel Therapeutics Biotech & Medicals Corporation (TW) 2025-04-17 — — US disclosed
WO-2025040139-A1 RNAI AGENT FOR INHIBITING DIACYLGLYCEROL-O-ACYLTRANSFERASE 2 EXPRESSION, AND APPLICATION THEREOF 云合智药（苏州）生物科技有限公司 2025-02-27 — — WO disclosed
WO-2001039777-A1 COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF OSI PHARMACEUTICALS, INC. (US) 2001-06-07 — — WO disclosed
WO-2001040181-A1 ACRYLOYL PEPTIDIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR AGENTS PHARMACIA ITALIA S.P.A. (IT) 2001-06-07 — — WO disclosed
US-6207858-B1 ELIMINATES THE NEED FOR ION EXCHANGE CHROMOTOGRAPHIC SEPARATION OF INTERMEDIATES, USEFUL AS BI-FUNCTIONAL CHELATORS IN RADIOIMMUNOTHERAPY AND IMAGING, DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA), SUITABLE FOR IDEC PHARMACEUTICALS CORPORATION 2001-03-27 — — US disclosed
EP-1082120-A1 PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE OSI Pharmaceuticals, Inc. (US) 2001-03-14 — — EP disclosed
WO-2000051976-A1 REGIOSELECTIVE SYNTHESIS OF DTPA DERIVATIVES IDEC PHARMACEUTICALS CORPORATION (US) 2000-09-08 — — WO disclosed
WO-2000009116-A1 GRP RECEPTOR LIGANDS SMITHKLINE BEECHAM CORPORATION (US) 2000-02-24 — — WO disclosed
WO-2000002864-A1 PRECUSORS FOR PNA-MONOMERS MARTENS JUERGEN (DE) 2000-01-20 — — WO disclosed
WO-1999062518-A1 PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE OSI PHARMACEUTICALS, INC. (US) 1999-12-09 — — WO disclosed
EP-0878194-A1 REMEDIES OR PREVENTIVES FOR AIDS SANKYO COMPANY LIMITED (JP) 1998-11-18 — — EP disclosed
EP-0565567-B1 AMIDES OF ANTIBIOTIC GE 2270 FACTORS LEPETIT SPA (IT) 1995-01-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250120967-A1 TYROSINE KINASES INHIBITORS AND USES THEREOF LCK, LTK, HIF1AN MEN1 4694/4885GAA 376/4885KMT2A 93/4885
US-12486285-B2 BCL6 inhibitors BCL6, BCL6B, BCL3 MEN1 708/4885GAA 3224/4885KMT2A 757/4885
US-20260042776-A1 BCL6 INHIBITORS BCL6, BCL6B, BCL9 MEN1 2126/4885GAA 4338/4885KMT2A 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.